CD47 and non-Hodgkin lymphoma: Recently, a Phase 1b study involving patients with relapsed or refractory non-Hodgkin’s lymphoma showed that the anti-CD47 antibody, Hu5F9-G4, combined with rituximab, exerted promising activity in patients with aggressive and indolent lymphoma, without showing clinically significant safety events [30].